News | June 10, 2026
Viyash Scientific to acquire Italy’s BioForLife for Rs. 188 crore
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Subscribe To Our Newsletter & Stay Updated
